Vol 91, No 4 (2020)
Research paper
Published online: 2020-03-30

open access

Page views 1314
Article views/downloads 976
Get Citation

Connect on Social Media

Connect on Social Media

Presence of human papilloma virus in Caucasian women living in the central Europe diagnosed with vulvar intraepithelial neoplasia

Marta Robenek1, Anita Olejek1, Lukasz Witek1, Aleksandra Augusciak-Duma1, Bogna Drozdzowska1, Iwona Gabriel1
Pubmed: 32236934
Ginekol Pol 2020;91(4):181-184.


Objectives: The role of human papilloma virus (HPV) in the development of cancerous states of female reproductive tract
has been widely debated. However, the information about presence of HPV in the Caucasian women living in the central
Europe diagnosed with vulvar intraepithelial neoplasia (VIN) is missing. So far, no recommendation was made to complete
HPV detection in time of vulvar biopsy or after the results of positive VIN are obtained. We aimed to assess the presence of
HPV in women with vulvar intraepithelial neoplasia diagnosed at the Department of Gynecology, Obstetrics and Oncological
Gynecology in Bytom, Poland.
Material and methods: The retrospective examination of 120 consecutive vulvar biopsies obtained from women with
persistent vulvar itching was done. Only patients with diagnosis of VIN were included in the further analysis. HPV DNA
was detected using HPV Linear Array Genotyping Test including 14 HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, 66, 68).
Results: Out of 120 vulvar samples retrieved, 18 women were positive for VIN, including15 usual VIN (uVIN) and three differentiated
type (dVIN ). 10 samples were eligible for DNA detection. HPV DNA was found in two women with uVIN (HPV
16 and 51).
Conclusions: It is advisable to recommend HPV genotyping in women with VIN, regardless of their age and histologic type.
The incidence of HPV infection in Caucasian women from the central Europe with VIN should be further studied.

Article available in PDF format

View PDF Download PDF file


  1. de Freitas AC, Coimbra EC, Leitão Md. Molecular targets of HPV oncoproteins: potential biomarkers for cervical carcinogenesis. Biochim Biophys Acta. 2014; 1845(2): 91–103.
  2. Tommasino M. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol. 2014; 26: 13–21.
  3. Bryant D, Rai N, Rowlands G, et al. Human papillomavirus type distribution in vulval intraepithelial neoplasia determined using PapilloCheck DNA Microarray. J Med Virol. 2011; 83(8): 1358–1361.
  4. Hart WR. Vulvar intraepithelial neoplasia: historical aspects and current status. Int J Gynecol Pathol. 2001; 20(1): 16–30.
  5. Kowalewska M, Szkoda MT, Radziszewski J, et al. The frequency of human papillomavirus infection in polish patients with vulvar squamous cell carcinoma. Int J Gynecol Cancer. 2010; 20(3): 434–437.
  6. Nowakowski A, Arbyn M, Turkot MH, et al. A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention. Eur J Cancer Prev. 2020; 29(2): 157–164.
  7. Võrno T, Lutsar K, Uusküla A, et al. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage. Vaccine. 2017; 35(46): 6329–6335.
  8. Hamsikova E, Smahelova J, Ludvikova V, et al. The prevalence of HPV infections in HPV-vaccinated women from the general population. APMIS. 2017; 125(6): 585–595.
  9. Pils S, Gensthaler L, Alemany L, et al. HPV prevalence in vulvar cancer in Austria. Wien Klin Wochenschr. 2017; 129(21-22): 805–809.
  10. Woo YL, Damay I, Stanley M, et al. The use of HPV Linear Array Assay for multiple HPV typing on archival frozen tissue and DNA specimens. J Virol Methods. 2007; 142: 226–230.
  11. Serrano B, de Sa, Tous S, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52, 58. Eur J Cancer. 2015; 51: 1732–1741.
  12. Wakeham K, Kavanagh K, Cuschieri K, et al. HPV status and favourable outcome in vulvar squamous cancer. Int J Cancer. 2017; 140(5): 1134–1146.
  13. Riethdorf S, Neffen EF, Cviko A, et al. p16INK4A expression as biomarker for HPV 16-related vulvar neoplasias. Hum Pathol. 2004; 35(12): 1477–1483.
  14. Srodon M, Stoler MH, Baber GB, et al. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol. 2006; 30(12): 1513–1518.
  15. Mazellier S, Dadone-Montaudie B, Chevallier A, et al. Papillomavirus genotyping on formaldehyde fixed paraffin-embedded tissue in vulva intraepithelial neoplasia. Arch Gynecol Obstet. 2017; 296: 811–817.
  16. van de Nieuwenhof HP, Massuger LF, van der Avoort IAM, et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur J Cancer. 2009; 45(5): 851–856.
  17. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005; 191(2): 182–192.
  18. Giuliano AR, Joura EA, Garland SM, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecol Oncol. 2019; 154(1): 110–117.